1,721,029 research outputs found
CUSPIDI
No full textCuspidi is the new play by Valerio Leoni, winner of the Biennale College Theatre call for Directors under 35 for the two-year period 2022/2023. A Roman director, actor and playwright, born in 1988, Valerio Leoni worked as a director while conducting research into theatre in Poland, Germany, Denmark, Spain and Italy. The founder in 2015 of the Agiteatro company, he is the artistic director, along with Sofia Guidi, of the cultural centre Labirion Officine Trasversali, which he founded in Rome in 2018. It was at Labirion that in 2022 Leoni developed the original idea for Cuspidi.
Selected from a shortlist of six candidates because “his artistic career moves beyond and away from a visually and linguistically realistic trajectory to redirect the investigation by instilling into it an emotional tone that can cast light on, move or freeze the bodies and the plurality of their monologuing voices within a mental landscape imagined by Magritte”, Valerio Leoni creates his play around three characters-emotions: A consisting of Screams (Sofia Guidi) which “contains within it the concepts of discomfort, difficulty of living in the world, expressive confusion”; B consisting of Dust (Sara Giannelli), which “maintains its own gaze turned towards the past, remaining disunited”; C consisting of Boxes (Jacopo Provenzano), which “relies on classification and organization as a weapon to defend itself against the chaos of the world”. Self-standing universes, with their own habitat, substance and rhythm, but forced to share the same space, at the end of the play A B C will emerge from their conditions as islands and re-establish a dialogue
La qualità dei prodotti alimentari destinati ad un'alimentazione particolare: aspetti applicativi della normativa comunitaria
No full textActivated sludge biodegradation test as a screening method to evaluate persistence of pesticides in soil
No full text
Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses
No full textThe great hopes raised by the discovery of the immunoregulatory cytokine interleukin 12 (IL-12) as an anticancer agent were marred during early clinical experimentation because of severe adverse effects, which prompted a search for alternative formulations and routes of administration. Onco-immunotherapeutic viruses (OIVs) are wild-type or genetically engineered viruses that exert antitumor activity by causing death of the tumor cells they infect and by overcoming a variety of immunosuppressive mechanisms put in place by the tumors. OIVs have renewed the interest in IL-12, as they offer the opportunity to encode the cytokine transgenically from the viral genome and to produce it at high concentrations in the tumor bed. A large body of evidence indicates that IL-12 serves as a potent adjuvant for the immunotherapeutic response elicited by OIVs in murine tumor models. The list of OIVs includes onco-immunotherapeutic herpes simplex, adeno, measles, Newcastle disease, and Maraba viruses, among others. The large increase in IL-12-mediated adjuvanticity was invariably observed for all the OIVs analyzed. Indirect evidence suggests that locally delivered IL-12 may also increase tumor antigenicity. Importantly, the OIV/IL-12 treatment was not accompanied by adverse effects and elicited a long-lasting immune response capable of halting the growth of distant tumors. Thus, OIVs provide an avenue for reducing the clinical toxicity associated with systemic IL-12 therapy, by concentrating the cytokine at the site of disease. The changes to the tumor microenvironment induced by the IL-12-armed OIVs primed the tumors to an improved response to the checkpoint blockade therapy, suggesting that the triple combination is worth pursuing in the future. The highly encouraging results in preclinical models have prompted translation to the clinic. How well the IL-12-OIV-checkpoint inhibitors' combination will perform in humans remains to be fully investigated
Bone-fracture incidence rate in two Italian regions with different fluoride concentration levels in drinking water
No full textBone fracture incidence rate in two italian regions with different fluoride concentration levels in drinking water
No full textSeparation of pesticides, related compounds, polychlorobiphenyls and other pollutants into four groups by silica‐gel microcolumn chromatography (application to surface water analysis)
No full textMulti‐residue analyses of pesticides and related compounds generally require clean‐up procedures for the elimination of interfering substances. An analytical procedure for use in the recovery and determination of pesticides and other pollutants in water samples is described, in which the purification of the extracts is improved by the separation of pesticides into four groups. The separation of pesticides by silica‐gel microcolumn chromatography is explained in detail. Copyright © 1991 John Wiley & Sons, Lt
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
